Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Age: 18 years and over

Healthy Volunteers:

This study is NOT accepting healthy volunteers

Inclusion Criteria:

* Age ≥ 18 years * ICD implanted for primary prevention for HFrEF (either ICM or NICM) with remote monitoring capability * Current treatment with metoprolol succinate and willing to switch to carvedilol * LVEF \<50% during the past 12 months prior to consent

Exclusion Criteria:

* Unwilling or unable to follow the protocol * Treatment with any other ßB than metoprolol succinate or no ßB treatment * Known prior intolerance or contraindication to carvedilol * Systolic blood pressure \<100 mmHg * Enrollment in another clinical trial * Inability or unwilling to consent

Interventions:

DRUG: Metoprolol Succinate, DRUG: Carvedilol

Conditions:

Heart Failure With Reduced Ejection Fraction (HFrEF), Sudden Cardiac Death, Ventricular Arrhythmia, Implantable Cardioverter Defibrillator (ICD), Beta-blocker Therapy, Cardiomyopathy

Keywords:

arrhythmia, heart failure, ICD, implantable cardioverter defibrillator, ICD shock, carvedilol, metoprolol succinate, beta-blocker

Contact(s): Mehmet Aktas, M.D. - Mehmet_Aktas@URMC.Rochester.edu

Principal Investigator:

Phase: PHASE4

IRB Number:

System ID: NCT06964464

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Email this study information to me

Contact the study team